Unique ID issued by UMIN | UMIN000052304 |
---|---|
Receipt number | R000059701 |
Scientific Title | Assessment of flavonoid Pharmacokinetics following single capsule intake in healthy adult men |
Date of disclosure of the study information | 2023/09/25 |
Last modified on | 2024/07/31 15:30:33 |
Assessment of flavonoid Pharmacokinetics following single capsule intake in healthy adult men
Assessment of flavonoid Pharmacokinetics following single capsule intake in healthy adult men
Assessment of flavonoid Pharmacokinetics following single capsule intake in healthy adult men
Assessment of flavonoid Pharmacokinetics following single capsule intake in healthy adult men
Japan |
Healthy individuals
Adult |
Others
NO
Obtaining fundamental information on flavonoid pharmacokinetics after single capsule intake in healthy adult men
Pharmacokinetics
Flavonoid plasma kinetics parameters
(Secondary outcomes)
Urinary flavonoid excretion rate
(Safety evaluation)
Frequency of adverse events during the period from intake of the test food to the following day, general physical findings (subjective symptoms, objective findings), vital signs (body weight, body temperature, blood pressure, pulse rate), blood test items, urinalysis items
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Active
2
Prevention
Food |
Test food 1 (single ingestion) -Washout period-Test food 2 (single ingestion)
Test food 2 (single ingestion) -Washout period-Test food 1 (single ingestion)
20 | years-old | <= |
60 | years-old | >= |
Male
1)Individuals who voluntarily giving written informed consent.
2)Healthy adult males aged between 20 and 60.
3)Individuals able to intake the test food (capsule).
4)Individuals who can intake test foods, etc., take blood samples, take urine samples, and stay quiet and rest on the schedule indicated by investigators.
1)Individuals whose clinical inspection results are outside of the normal range and who are estimated inappropriate to this study by principal investigator.
2)Individuals with current or previous disorders of the gastrointestinal, cardiovascular, and endocrine systems who are determined to be ineligible for the study by the investigator.
3)Individuals with smoking habits.
4)As a general rule, individuals who regularly use medicines for treatnemnt of diseases.
5)Individuals with food allergy.
6)Individuals who are currently participating in another study or plan to participate during the study period
7)Individuals who are estimated inappropriate to participate to this study by principal investigator.
18
1st name | Yasutaka |
Middle name | |
Last name | Ikeda |
Otsuka Pharmaceutical Co., Ltd.
Otsu Nutraceuticals Research Institute
520-0002
3-31-13 Saigawa, Otsu, Shiga, Japan
077-521-8835
Ikeda.Yasutaka@otsuka.jp
1st name | Hidemasa |
Middle name | |
Last name | Toya |
HUMA R&D CORP
Clinical Development Department
108-0014
Round Cross Tamachi 9F, 5-31-19 Shiba, Minato-ku, Tokyo 108-0014 Japan
03-3431-1260
toya@huma-rd.co.jp
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Profit organization
Miyake Clinic Institutional Review Board
4-2-17 Komagome, Toshima-ku, Tokyo 170-0003 Japan
03-6903-7211
jim@medipharma.co.jp
NO
2023 | Year | 09 | Month | 25 | Day |
Unpublished
18
No longer recruiting
2023 | Year | 09 | Month | 06 | Day |
2023 | Year | 09 | Month | 08 | Day |
2023 | Year | 09 | Month | 26 | Day |
2023 | Year | 11 | Month | 30 | Day |
2023 | Year | 12 | Month | 12 | Day |
2023 | Year | 12 | Month | 19 | Day |
2025 | Year | 07 | Month | 31 | Day |
2023 | Year | 09 | Month | 25 | Day |
2024 | Year | 07 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059701